Development and Evaluation of Losartan Potassium Floating Matrix Tablet

  • Prateek Kumar Chaturvedi School of Pharmacy, LNCT University, Bhopal, M. P., India
  • Rajesh Gour School of Pharmacy, LNCT University, Bhopal, M. P., India
  • Janki Prasad Rai School of Pharmacy, LNCT University, Bhopal, M. P., India
  • Akhlesh Kumar Singhai School of Pharmacy, LNCT University, Bhopal, M. P., India

Abstract

The present study was aimed towards the development of controlled release formulations of Losartan Potassium based on designed to enhance the bioavailability by prolonging its duration in the stomach via the floating dosage forms with controlled release. This study was intended to evaluate the influence of formulation variables like levels of polymer, amount of mannitol concentrations, and coating solution ratios of semi permeable membrane on the drug release from the developed formulations. Thus, there is a strong clinical need and market potential for a dosage form that will deliver Losartan Potassium in a controlled manner to a patient needing this therapy, thereby resulting in a better patient compliance. This study was designed to enhance the bioavailability of drug by prolonging its duration in the stomach via the floating dosage forms with controlled release. Floating matrix tablets of Losartan Potassium were prepared by the direct compression method, using locust bean gum and HPMC K 15M as polymers and Sodium bicarbonate as floating agent. The effect of the nature of polymers was studied by preparing various formulations of tablets. In all these formulations, a constant amount of drug (100 mg) was maintained. The blend was initially characterized for pre-compression and post- compression parameters. Pre-compression characterization was done for angle of repose, bulk density, tapped density, Carr’s index, and Hausner’s ratio. The results of pre-compression characterization were indicated good to excellent flow characteristics. Post-compression characterization includes thickness, hardness, friability, weight variation, drug content, buoyancy lag time, floating time and in-vitro drug release. All the results were satisfactory as per the guideline of pharmacopoeia. The in vitro drug release studies found that formulations LPFT4 showed best sustained release profile in 24 hrs. Among the nine formulations (LPFT1 to LPFT9) prepared formulations LPFT4 was found to be the best formulations in terms of sustained drug release. Drug release kinetics was performed by using various kinetic models such as Zero order, First order, Korsmeyer- Peppas and Higuchi’s equation and followed supercase II transport diffusion kinetic models.


Keywords: Oral drug delivery system, Gastroretentive technology, losartan potassium, floating tablet, matrix tablet

Keywords: Oral drug delivery system, Gastroretentive technology, losartan potassium, floating tablet, matrix tablet

Downloads

Download data is not yet available.

Author Biographies

Prateek Kumar Chaturvedi, School of Pharmacy, LNCT University, Bhopal, M. P., India

School of Pharmacy, LNCT University, Bhopal, M. P., India

Rajesh Gour, School of Pharmacy, LNCT University, Bhopal, M. P., India

School of Pharmacy, LNCT University, Bhopal, M. P., India

Janki Prasad Rai, School of Pharmacy, LNCT University, Bhopal, M. P., India

School of Pharmacy, LNCT University, Bhopal, M. P., India

Akhlesh Kumar Singhai, School of Pharmacy, LNCT University, Bhopal, M. P., India

School of Pharmacy, LNCT University, Bhopal, M. P., India

References

1. Fellermann K, Stange EF, "Defensins - innante immunity at the epithelial frontier", European Journal Gastroenterology Hepatology, 2001; 13:771- 5. https://doi.org/10.1097/00042737-200107000-00003
2. Gewirtz AT, "Intestinal epithelial pathobiology: past, present and future", Best Pract Research Clinical Gastroenterology, 2002, 16, 851-859. https://doi.org/10.1053/bega.2002.0339
3. Singh BN, Kim KH. In Drug Dlivery: Oral Route. In: Swarbrick J, editor. Encyclopedia of Pharmaceutical Technology. 3rd Edn; New York: Informa Healthcare USA, Inc., USA, 2007, pp 1242- 1244.
4. Friend DR, "New oral delivery systems for treatment of inflammatory bowel disease", Advanced Drug Delivery Reviews, 2005; 57:247-65. https://doi.org/10.1016/j.addr.2004.08.011
5. Someshwar K, Chithaluru K, Ramarao T, Kumar KK. Formulation and evaluation of effervescent floating tablets of tizanidine hydrochloride. Acta Pharm. 2011; 61(2):217-226. https://doi.org/10.2478/v10007-011-0015-5
6. Kotreka UK, Adeyeye MC. Gastroretentive floating drug-delivery systems: a critical review. Crit. Rev. Ther. Drug Carrier Syst. 2011; 28(1):47-99. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v28.i1.20
7. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release 2000; 63(3):235- 259. https://doi.org/10.1016/S0168-3659(99)00204-7
8. Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK, Baboota S. Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2007; 67(1):196-201. https://doi.org/10.1016/j.ejpb.2006.12.015
Statistics
42 Views | 3 Downloads
How to Cite
1.
Chaturvedi PK, Gour R, Rai JP, Singhai AK. Development and Evaluation of Losartan Potassium Floating Matrix Tablet. JDDT [Internet]. 15Jun.2022 [cited 1Jul.2022];12(3-S):106-14. Available from: https://jddtonline.info/index.php/jddt/article/view/5388